Patents by Inventor Arnau BUSQUET-GARCIA

Arnau BUSQUET-GARCIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders
    Publication number: 20230226076
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Application
    Filed: September 15, 2022
    Publication date: July 20, 2023
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Mathilde METNA, Stéphanie MONLEZUN, Arnau BUSQUET-GARCIA, Daniela COTA, Giovanni MARSICANO, Jean-Michel REVEST, Monique VALLEE
  • 3?-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders
    Patent number: 11484537
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 1, 2022
    Assignees: AELIS FARMA, INSERM (Institut National de la Santé et de la Recherche Médicale), UNIVERSITE DE BORDEAUX
    Inventors: Pier Vincenzo Piazza, Sandy Fabre, Mathilde Metna, Stéphanie Monlezun, Arnau Busquet-Garcia, Daniela Cota, Giovanni Marsicano, Jean-Michel Revest, Monique Vallée
  • 3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of Cannabinoids-Related Disorders
    Publication number: 20210030768
    Abstract: The present invention generally relates to a specific pregnenolone derivative for its use for the treatment of a Cannabinoids-Related Disorder. More particularly, the invention relates to a compound of Formula (I) for its use in the treatment of a Cannabinoids-Related Disorder. Indeed, the compound of the invention is in vivo very potent in inhibiting the effects of THC, and is able to inhibit both unconditioned and conditioned effects of THC including THC self-administration and reinstatement in THC seeking in non-human primates.
    Type: Application
    Filed: February 20, 2019
    Publication date: February 4, 2021
    Inventors: Pier Vincenzo PIAZZA, Sandy FABRE, Mathilde METNA, Stephanie MONLEZUN, Arnau BUSQUET-GARCIA, Daniela COTA, Giovanni MARSICANO, Jean-Michel REVEST, Monique VALLEE
  • Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
    Patent number: 9662320
    Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
    Type: Grant
    Filed: March 19, 2013
    Date of Patent: May 30, 2017
    Assignee: Universitat Pompeu Fabra
    Inventors: Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez
  • Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities
    Publication number: 20160067235
    Abstract: The invention relates to antagonists of the cannabinoid receptor CBI for use in the treatment and prevention of diseases associated with neural dendritic abnormalities, such as Down's syndrome, Angelman's syndrome, Rett syndrome and tuberous sclerosis. More specifically, the invention provides a method of treatment or prevention of such diseases by the administration of the compound rimonabant.
    Type: Application
    Filed: March 19, 2013
    Publication date: March 10, 2016
    Inventors: Andres Ozaita Mintegui, Arnau Busquets Garcia, Rafael Maldonado Lopez